Biography for John Carroll
John D. Carroll is a biotech analyst with 32 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.
Articles by John Carroll
Gen X largely shrugged off call for H1N1 shots
About 2 of every 3 American adults aged 36 to 39 tracked the frenzy of reports that erupted after the swine flu pandemic broke out and concluded that there was something there that was at least...
Hep A vax study underscores need for long-term campaigns
A new survey out from the CDC demonstrates just how potent a recommendation for vaccinations can be, and how quickly parents can overlook a jab when they aren't being urged repeatedly to provide...
Paragon nabs $15M filovirus vax contract from DoD
The U.S. Department of Defense has awarded Paragon Bioservices, a contract manufacturing organization, a $15 million contract to develop a mammalian process to manufacture vaccines for filoviruses,...
Confident Inovio chief pushes ahead on universal flu vaccine
Inovio Pharmaceuticals' irrepressible Joseph Kim gets the spotlight at U.S. News & World Report, which highlights the company's work on a universal flu vaccine and the CEO's certainty...
Merck spinout nails promising study on hep C vaccine
A group of European investigators working in league with a small biotech spun out of Merck four years ago has claimed an early-stage success with a small human trial that has generated positive
Journal calls autism study "an elaborate fraud"
The prestigious British Medical Journal has put one last nail in the coffin that's been fashioned to bury the professional reputation of Andrew Wakefield, the controversial researcher fingered as the
Novartis files for Bexsero OK
Novartis has submitted its meningococcal B vaccine Bexsero to the EU for marketing approval. "The Bexsero submission in the EU is an important milestone toward achieving the world's first
Pfizer hops on board Phylogica's vax discovery platform
Pfizer ($PFE) has turned to Australia's Phylogica for help in finding a new generation of peptide-based vaccines. In exchange for $500,000 upfront and up to $134 million in milestones, Phylogica will
Novartis blueprints $36M vaccine research lab in NC
Novartis ($NVS) has blueprinted plans for a $36 million vaccine research lab in Holly Springs, NC, and plans to fill about 100 high-paying jobs to staff the addition. The expansion follows the
Motavizumab failure shifts spotlight to RSV vaccines
The news this week that AstraZeneca ($AZN) is writing off its big motavizumab program for RSV has shifted the spotlight to a slate of earlier stage compounds as well as vaccines. The Wall Street
Anal cancer vax gets FDA green light
Merck has won approval for a new indication of its HPV vaccine Gardasil. The FDA gave its OK to start selling Gardasil to prevent anal cancer. Investigators presented data demonstrating that Gardasil
Vical touts animal study of vax adjuvant
Vical announced today that the company's Vaxfectin adjuvant significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents
FDA lifts hold on Novavax RSV vaccine trial
Shares of Novavax ($NVAX) surged this morning on the news that the FDA has lifted its clinical hold on a Phase I study of an experimental RSV vaccine. Back in November the biotech reported that it
Single therapeutic vaccine has potential to fight multiple conditions
A translational team of experts in Europe say they have identified a protein which is produced naturally in the human body and can be used as a therapeutic vaccine capable of fighting a range of
Replica vaccine offers new strategy in fight against polio
Backed with funds from the Bill and Melinda Gates Foundation, an international team of top vaccine researchers has come together to explore the potential of a new type of polio vaccine that "tricks"
Merck joins PATH on next-gen malaria vax program
Merck ($MRK) has signed on to work with the groundbreaking PATH Malaria Vaccine Initiative and the NYU Langone Medical Center on a next-generation malaria vaccine that will attempt to ward off the
Fauci outlines R&D challenges to universal flu vaccine
Developing a universal flu shot is one of the Holy Grails of the vaccine industry. But the long research road to the marketplace will be long and littered with challenging hurdles, according to
Breakthrough meningitis vaccine costs only 50 cents a jab
Working with money from the Bill and Melinda Gates Foundation, a team of experts from Seattle-based PATH and the World Health Organization were able to develop a new vaccine for meningitis that costs
WikiLeaks spotlights secret catalog of vulnerable vax facilities
During the recent swine flu pandemic, U.S. officials were bitterly frustrated by the need to rely on foreign vaccine makers to supply the bulk of the flu shots needed to calm an initially panicked
Wary J&J says it may be forced to renegotiate Crucell buyout
J&J has made it crystal clear that it still wants to complete its planned buyout of the Dutch biotech Crucell. But despite its hunger to build a major vaccine initiative on the foundation of the
Sanofi launches PhII study of C. diff vaccine
Sanofi Pasteur has launched an ambitious mid-stage clinical trial for an experimental new vaccine that will attempt to thwart the rising risk of hospital-acquired Clostridium difficile infection.
Bavarian Nordic reviewing partners for cancer vax
Bavarian Nordic says it has gathered between five and nine term sheets from potential partners for its experimental prostate cancer vaccine. The company's business development chief, Juergen
Personalized cancer vax helps keep patients tumor-free
Dartmouth investigators say that a personalized dendritic cell vaccine has produced a solid set of five-year survival data demonstrating its effectiveness at keeping patients cancer-free after their
Novartis and Venter team on faster vaccine development
Novartis is turning to J. Craig Venter to help blaze a development shortcut that can carve weeks off the time it takes to ramp up production of a new flu vaccine. One of the bottlenecks that appeared
Chief Justice dumps stock so he can hear vax case
Chief Justice John Roberts has sold all his Pfizer stock, in part so he can participate in a case that will determine if vaccine makers are guarded against certain liability suits by the federal
Latest Commentary